Fetal Losses
Conditions
Keywords
Foetal loss, complement, antiangiogenic factors, Repeated fetal losses
Brief summary
The aim of the study is to assess the role of complement dysregulation and its impact on antiangiogenic factors (soluble Flt1 and endoglin) in patients with foetal losses.
Detailed description
Females with medical history of repeated foetal losses will have blood sampling to perform analyses. If pregnant, blood sampling will be performed at different times throughout the pregnancy. Controls will be females without medical history of repeated foetal losses. They will also have blood sampling to perform analyses. If pregnant, blood sampling will be performed at different times throughout the pregnancy. Blood analyses will focus on : * mutations in genes coding for molecules that modulate complement activity * serum levels of sFlt1 and endoglin and their link to complement activation
Interventions
OTHERblood sample
blood sampling at inclusion and throughout pregnancy when pregnant
Sponsors
Nantes University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Inclusion criteria for females with repeated fetal losses: * Age\> 18 * Female affiliated to French health insurance (Social Security), * Informed consent form signed * Patient with history of at least three foetal losses without any cause found (chromosomal abnormalities, uterine malformations, endocrine disorders, etc.)
Exclusion criteria
for females with repeated fetal losses : * Patient not fulfilling inclusion criteria * Age \> 40 * Female unable to understand benefits and risks of protocol * Female with history of repeated foetal losses of infectious or endocrine origin. Inclusion criteria for females without repeated fetal losses: * Age\> 18 * Female affiliated to the French health insurance (Social Security) * Informed consent form signed * Female without history of repeated foetal losses
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mutations in genes coding for molecules that modulate complement activity | day1 (at inclusion) | to determine frequency of mutations of genes (membrane-cofactor protein (MCP), decay accelerating factor (DAF), ....) involved in complement activation : Profiles of these genes will be analysed in blood sample of females with medical history of repeated foetal losses and compared to those analysed in blood sample of females without medical history of repeated foetal losses. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum levels of sFlt1 and endoglin and their link to complement activation markers | 4 weeks post pregnancy start | To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses. |
| serum levels of sFlt1 and endoglin and their link to complement activation | 8 weeks post pregnancy start | To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses. |
Countries
France
Outcome results
None listed